- Home
- NRIX vs CLDX Comparison
NRIX vs CLDX Comparison
Compare NRIX & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NRIX | CLDX |
|---|---|---|
| Founded | 2009 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.6B |
| IPO Year | 2020 | 1995 |
Fundamental Metrics
Financial Performance| Metric | NRIX | CLDX |
|---|---|---|
| Price | $23.17 | $35.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 10 |
| Target Price | $30.50 | ★ $46.60 |
| AVG Volume (30 Days) | ★ 1.9M | 1.3M |
| Earning Date | 04-08-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $76,987,000.00 | $12,743,000.00 |
| Revenue This Year | N/A | $111.39 |
| Revenue Next Year | $48.05 | $235.85 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 99.31 | 87.78 |
| 52 Week Low | $8.20 | $19.72 |
| 52 Week High | $25.09 | $40.30 |
Technical Indicators
Market Signals| Indicator | NRIX | CLDX |
|---|---|---|
| Relative Strength Index (RSI) | 61.64 | 48.89 |
| Support Level | $14.63 | $28.51 |
| Resistance Level | $24.98 | $40.30 |
| Average True Range (ATR) | 1.25 | 1.76 |
| MACD | -0.23 | -0.38 |
| Stochastic Oscillator | 50.58 | 19.56 |
Price Performance
Historical ComparisonAbout NRIX Nurix Therapeutics Inc.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.